Prestige Consumer Healthcare Inc. Reports Decline in Q2 Profit, Surpassing Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Should l Buy PBH?
Source: NASDAQ.COM
Earnings Report: Prestige Consumer Healthcare Inc. reported a second-quarter profit of $42.21 million, down from $54.37 million last year, but exceeded analysts' expectations of $0.97 per share with adjusted earnings of $1.07 per share.
Revenue Decline: The company's revenue decreased by 3.4% to $274.11 million compared to $283.78 million in the same quarter last year.
Earnings Per Share Comparison: The earnings per share (EPS) for the quarter was $0.86, compared to $1.09 in the previous year.
Future Guidance: Prestige Consumer Healthcare provided full-year EPS guidance of $4.54 - $4.58 and revenue guidance of $1,100 - $1,115 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBH
Wall Street analysts forecast PBH stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 66.960
Low
66.00
Averages
76.00
High
86.00
Current: 66.960
Low
66.00
Averages
76.00
High
86.00
About PBH
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Doseology Sciences Launches New Energy Product Line
- Market Trend Analysis: The global health and wellness sector is projected to reach $6 trillion in consumer spending by 2026, driven by rising demand for functional products, compelling companies to adapt to the FDA's updated 'Healthy' labeling framework to meet market needs.
- New Product Launch: Doseology Sciences launched caffeine-based energy pouches in January 2026, marking the entry of its Feed That Brain brand into the rapidly growing oral pouch market, utilizing a sugar-free, non-carbonated, portable design to cater to consumer demand for healthier alternatives.
- Strategic Acquisition: Doseology acquired the Feed That Brain brand for $400,000 in August 2025, enhancing its competitive edge in the functional product space, while also appointing Joseph Mimran as a strategic advisor to further bolster brand influence.
- Optimistic Market Outlook: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, indicating strong market demand, and Doseology's product innovations align perfectly with this trend, likely driving future company growth.
See More
Doseology Sciences Launches New Energy Product Line
- Market Trend Analysis: The global health and wellness sector is projected to reach $6 trillion in consumer spending by 2026, driven by rising demand for functional products, compelling companies to adapt to the FDA's new labeling framework to meet consumer preferences for sugar-free and preservative-free options, thereby enhancing market competitiveness.
- New Product Launch: Doseology Sciences initiated pilot production of caffeine-based energy pouches in January 2026, marking the entry of its Feed That Brain brand into the rapidly growing oral pouch market, which is expected to attract consumers seeking portable energy supplements.
- Strategic Acquisition: Doseology acquired the Feed That Brain brand for $400,000 in August 2025, leveraging its strengths in functional product design to drive compliant new product development and further expand market share.
- Market Potential: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, indicating strong market demand, and Doseology's product innovations align perfectly with this trend, likely driving future growth for the company.
See More
Prestige Consumer Healthcare Reports Q3 2026 Earnings with Strategic Insights
- Sales Performance Review: Prestige Consumer Healthcare reported Q3 sales of $283 million, slightly exceeding forecasts despite a 2.4% year-over-year decline, indicating resilience in its diversified customer base amidst macroeconomic challenges and positive order trends in growth channels.
- Profitability Analysis: The adjusted diluted EPS was $1.14, down from $1.22 in the prior year, primarily due to lower sales and increased general and administrative costs, reflecting challenges in cost control for the company.
- Cash Flow and Capital Allocation: Free cash flow for the first nine months reached $208.8 million, up 12.9% year-over-year, while the company repurchased over $150 million in shares, demonstrating a commitment to shareholder returns and flexible capital allocation strategies.
- Future Outlook: The company narrowed its fiscal 2026 sales outlook to approximately $1.1 billion, with anticipated adjusted diluted EPS of $4.54, as management remains optimistic about ongoing improvements in Clear Eyes supply, emphasizing execution and incremental enhancements in core product supply.
See More
Prestige (PBH) Q3 2026 Earnings Call Transcript
See More
Prestige Consumer Healthcare Q3 Earnings Miss Expectations
- Earnings Report Disappointment: Prestige Consumer Healthcare reported a Q3 non-GAAP EPS of $1.14, missing expectations by $0.02, indicating pressure on profitability that could affect investor confidence.
- Revenue Decline: Q3 revenue was $283.4 million, down 2.4% year-over-year and missing market expectations by $3.12 million, reflecting challenges in the competitive landscape.
- Fiscal 2026 Outlook Adjustment: The company revised its FY26 revenue outlook to between $1.1 billion and $1.115 billion, indicating a cautious stance on future growth with an anticipated organic revenue decline of approximately 3%.
- Stable Cash Flow: Despite challenges, the company expects free cash flow to remain at $245 million or more, demonstrating robust cash management that may support future investments.
See More
2026 Stock Market and Economic Forecast from Barron’s Roundtable Experts
Market Concerns: Investors are increasingly worried about high valuations, index concentration, circular finance, persistent inflation, and rising government debt.
Geopolitical Developments: A significant geopolitical event occurred on January 3, with the capture of Venezuelan President Nicolás Maduro and his wife by U.S. troops, adding to market uncertainties.
See More
Doseology Sciences Launches New Energy Product Line
- Market Trend Analysis: The global health and wellness sector is projected to reach $6 trillion in consumer spending by 2026, driven by rising demand for functional products, compelling companies to adapt to the FDA's updated 'Healthy' labeling framework to meet market needs.
- New Product Launch: Doseology Sciences launched caffeine-based energy pouches in January 2026, marking the entry of its Feed That Brain brand into the rapidly growing oral pouch market, utilizing a sugar-free, non-carbonated, portable design to cater to consumer demand for healthier alternatives.
- Strategic Acquisition: Doseology acquired the Feed That Brain brand for $400,000 in August 2025, enhancing its competitive edge in the functional product space, while also appointing Joseph Mimran as a strategic advisor to further bolster brand influence.
- Optimistic Market Outlook: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, indicating strong market demand, and Doseology's product innovations align perfectly with this trend, likely driving future company growth.
See More
Doseology Sciences Launches New Energy Product Line
- Market Trend Analysis: The global health and wellness sector is projected to reach $6 trillion in consumer spending by 2026, driven by rising demand for functional products, compelling companies to adapt to the FDA's new labeling framework to meet consumer preferences for sugar-free and preservative-free options, thereby enhancing market competitiveness.
- New Product Launch: Doseology Sciences initiated pilot production of caffeine-based energy pouches in January 2026, marking the entry of its Feed That Brain brand into the rapidly growing oral pouch market, which is expected to attract consumers seeking portable energy supplements.
- Strategic Acquisition: Doseology acquired the Feed That Brain brand for $400,000 in August 2025, leveraging its strengths in functional product design to drive compliant new product development and further expand market share.
- Market Potential: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, indicating strong market demand, and Doseology's product innovations align perfectly with this trend, likely driving future growth for the company.
See More
Prestige Consumer Healthcare Reports Q3 2026 Earnings with Strategic Insights
- Sales Performance Review: Prestige Consumer Healthcare reported Q3 sales of $283 million, slightly exceeding forecasts despite a 2.4% year-over-year decline, indicating resilience in its diversified customer base amidst macroeconomic challenges and positive order trends in growth channels.
- Profitability Analysis: The adjusted diluted EPS was $1.14, down from $1.22 in the prior year, primarily due to lower sales and increased general and administrative costs, reflecting challenges in cost control for the company.
- Cash Flow and Capital Allocation: Free cash flow for the first nine months reached $208.8 million, up 12.9% year-over-year, while the company repurchased over $150 million in shares, demonstrating a commitment to shareholder returns and flexible capital allocation strategies.
- Future Outlook: The company narrowed its fiscal 2026 sales outlook to approximately $1.1 billion, with anticipated adjusted diluted EPS of $4.54, as management remains optimistic about ongoing improvements in Clear Eyes supply, emphasizing execution and incremental enhancements in core product supply.
See More
Prestige (PBH) Q3 2026 Earnings Call Transcript
See More
Prestige Consumer Healthcare Q3 Earnings Miss Expectations
- Earnings Report Disappointment: Prestige Consumer Healthcare reported a Q3 non-GAAP EPS of $1.14, missing expectations by $0.02, indicating pressure on profitability that could affect investor confidence.
- Revenue Decline: Q3 revenue was $283.4 million, down 2.4% year-over-year and missing market expectations by $3.12 million, reflecting challenges in the competitive landscape.
- Fiscal 2026 Outlook Adjustment: The company revised its FY26 revenue outlook to between $1.1 billion and $1.115 billion, indicating a cautious stance on future growth with an anticipated organic revenue decline of approximately 3%.
- Stable Cash Flow: Despite challenges, the company expects free cash flow to remain at $245 million or more, demonstrating robust cash management that may support future investments.
See More
2026 Stock Market and Economic Forecast from Barron’s Roundtable Experts
Market Concerns: Investors are increasingly worried about high valuations, index concentration, circular finance, persistent inflation, and rising government debt.
Geopolitical Developments: A significant geopolitical event occurred on January 3, with the capture of Venezuelan President Nicolás Maduro and his wife by U.S. troops, adding to market uncertainties.
See More
